Axovant raids Novartis, Spark and Sarepta for gene therapy experts

26 November 2018

Greg MacMichael, the former global head of cell and gene therapy technical development and manufacturing at Swiss pharma giant Novartis (NOVN: VX), is one of five new recruits to join Axovant Sciences (Nasdaq: AXON).

The Switzerland-based company has added the senior team members to strengthen its expertise in the development and commercialization of gene therapies for neurological and neuromuscular diseases.

Their skills will boost Axovant’s capabilities in gene therapy manufacturing, vector optimization, operations, clinical development, regulatory affairs and commercialization.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK